Buy Xarelto

Xarelto has a wide range of uses. It is used for the following diseases:

• arrhythmia;

 

• APS (antiphospholipid syndrome, which is accompanied by an increased ability of blood to clot);

 

• atrial fibrillation (atrial fibrillation (AF));

 

• in oncology;

 

• in chemotherapy;

 

• in varicose veins;

 

• CHD (coronary heart disease);

 

• ischemic stroke;

 

• myocardial infarction;

 

• in ACS (acute coronary syndrome);

 

• fractures (including femoral neck fractures);

 

• in operations involving prosthetics of the femoral head or knee joint;

 

• prosthetics of valves;

 

• in case of stenting;

 

• thrombosis (including deep vein thrombosis (DVT));

 

• pulmonary embolism (EP);

 

• in thrombophlebitis.

Inside, during the meal.

 

If the patient is unable to swallow the whole tablet, Xarelto® can be crushed and mixed with water or liquid food, such as apple puree, just before taking it. After taking the shredded tablet of Xarelto® it is necessary to eat immediately.

 

 

Prevention of stroke and systemic thromboembolism in patients with atrial fibrillation of non-clapanic origin

 

The recommended dose is 20 mg once a day.

 

For patients with impaired renal function (creatinine Cl is 30-49 ml/min) the recommended dose is 15 mg once a day.

 

Recommended maximum daily dose is 20 mg.

 

Duration of treatment: Xarelto® therapy should be considered as a long-term treatment as long as the benefit of treatment exceeds the risk of possible complications.

 

Actions in case of missing a dose: If you miss a new dose, you should take Xarelto® immediately and continue regular use of the drug the next day according to the recommended regimen. Do not double the dose taken to compensate the missed dose.

 

 

DVT and PE treatment and prevention of relapse DVT and PE

 

 

The recommended initial dose in the treatment of acute DVT or PE is 15 mg 2 times a day for the first 3 weeks, followed by a dose of 20 mg 1 time a day for further treatment and prevention of recurrence of DVT and PE.

 

After at least 6 months of DVT or PE treatment, the recommended dose of Xarelto® is 10 mg once a day or 20 mg once a day, depending on the individual ratio of risk of DVT or EP relapse and risk of bleeding.

 

The maximum daily dose is 30 mg (15 mg 2 times a day) during the first 3 weeks of treatment and maximum 20 mg with further use of the drug.

 

The minimum duration of treatment (at least 3 months) should be based on the assessment of reversible risk factors.

 

Actions in case of missing a dose:

 

It is important to follow the set dosing regime. If the next dose is missed with the dosing regime 15 mg 2 times a day, the patient should take Xarelto® immediately to reach the daily dose of 30 mg. Thus, 2 tablets of 15 mg can be taken in one dose. The next day, the patient should continue regular use of the drug according to the recommended regimen. If the next dose is missed in the dosing regime 20 mg once a day, the patient should immediately take Xarelto® and the next day continue regular use of the drug in accordance with the recommended regime.

• Xarelto® is contraindicated for patients with liver diseases accompanied by coagulopathy, which causes a clinically significant risk of bleeding.

 

• Xarelto® is not recommended for patients with Cl creatinine <15 ml/min.

 

• Xarelto® is contraindicated for pregnant women.

 

• Xarelto® is contraindicated for chidlren under 18.

 

• Xarelto® is contraindicated in lactation period.

 

• Xarelto® is contraindicated for people with congenital lactase deficiency, lactose intolerance, glucose-galactic malabsorption

Rare overdoses have been reported when taking rivaroxaban up to 600 mg without bleeding or other adverse reactions. Due to limited absorption, it is expected that the low-level plateau of the drug concentration will develop without further increase of its average plasma concentration when using doses exceeding the therapeutic ones, equal to 50 mg and more.

 

The specific antidote of rivaroxaban is unknown. In case of overdose, activated carbon can be used to reduce the absorption of rivaroxaban. Given the intense binding to plasma proteins, it is expected that rivaroxaban will not be excreted during dialysis.

The safety of Xarelto® was assessed in thirteen Phase III studies involving 53103 patients who took Xarelto®.

 

Frequent side effects:

• Bleeding.

 

Infrequent side effects:

• Bleeding from a wound;

 

• Abnormal liver function tests;

 

• Hematomas;

 

• Fainting;

 

• A sore throat;

 

• A toothache;

 

• Anxious feelings;

 

• Arthritis;

 

• Backache;

 

• Blisters on the skin;

 

• Depression;

 

• Sleeping problems;

 

• Dizziness;

 

• Indigestion;

 

• Inflammation of tissue lining the sinuses;

 

• Intense abdominal pain;

 

• Mouth irritation;

 

• Itching;

 

• Low energy;

 

• Muscle spasm;

 

• Urinary tract infection.

 

Rare side effects:

• Anaphylaxis;

 

• Stevens-Johnson Syndrome;

 

• Angioedema;

 

• Dress syndrome;

 

• Jaundice;

 

• Hemorrhagic stroke;

 

• Spinal epidural hematoma;

 

• Pulmonary bleeding;

 

• Abdominal hemorrhage;

 

• Stomach or intestine bleeding;

 

• Skull hemorrhage;

 

• Blockage of normal bile flow;

 

• Reduced thrombocytes;

 

• Hemiparesis;

 

• Hepatitis;

 

• Neutrophils;

 

• Subdural Intracranial Hemorrhage;

 

•  Low levels of granulocytes.

 

 

The active substance:     
Micronized rivaroxaban

 

Additional substances:

microcrystalline cellulose; crosscarmellose of sodium; hypromellose; lactose monohydrate; magnesium stearate; sodium lauryl sulphate.

 

Film membrane:

iron dye red oxide; hypromellose 15 cP (hydroxypropyl methylcellulose 2910); macrohead 3350 (polyethylene glycol (3350) ; titanium dioxide.

• Hypersensitivity to rivaroxaban or any of the auxiliary substances contained in the tablet;

 

• clinically significant active bleeding (e.g. intracranial hemorrhage, gastrointestinal bleeding);

 

• lesion or condition associated with an increased risk of major bleeding, e.g. existing or recently acquired gastrointestinal ulcer, presence of malignant tumours with a high risk of bleeding, recent brain or spinal cord injuries, brain, spinal cord or eye surgery, intracranial hemorrhage, diagnosed or suspected esophageal varicose veins, arteriovenous malformations, vascular aneurysms or brain or spinal cord pathology;

 

• complementary therapy with other anticoagulants such as non-fractionated heparin, low-molecular weight heparins (including enoxaparin, dalteparin), heparin derivatives (including fondaparinux), oral anticoagulants (including fondaparinux). varfarin, apixaban, dabigatran), except in cases of transition from or to rivaroxaban or when using unfractionated heparin in doses necessary for the functioning of a central venous or arterial catheter;

 

• liver diseases with coagulopathy, which causes a clinically significant risk of bleeding;

 

• pregnancy;

 

• the breastfeeding period;

 

• childhood and adolescence under 18 years of age (efficiency and safety of patients is not determined in this age group);

 

• severe renal impairment (creatinine Cl <15 ml/min) (clinical data on use of rivaroxaban are not available in this category of patients);

 

• congenital lactase deficiency, lactose intolerance, glucose-galactose malabsorption (due to the presence of lactose).

 

 

CAUTIOUSLY

 

• treatment of patients at increased risk of bleeding;

 

• treatment of patients with moderate renal impairment (creatinine Cl 30-49 ml/min), receiving simultaneously drugs increasing the concentration of rivaroxaban in plasma;

 

• rivaroxaban is not recommended in patients receiving systemic azole antifungal treatment (e.g. ketoconazole) or HIV protease inhibitors;

 

• patients receiving medications that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), antiaggregants, other antithrombotic drugs or selective serotonin re-uptake inhibitors (SRI) and selective serotonin re-uptake inhibitors and norepinephrine;

 

• patients with severe renal impairment (creatinine Cl 15-29 ml/min) or increased risk of bleeding and patients receiving concomitant systemic treatment with azole antifungal or HIV protease inhibitors should be closely monitored after treatment to detect complications in the form of bleeding in time.

At temperatures not exceeding 30 °C.

Keep out of the reach of children.

 

Shelf life: 3 years.

There is no prescription required!

You can legally buy Xarelto on our website without prescription!

You can buy Xarelto from our website absolutely legally.

 

Delivery is carried out to all countries in the world, which do not have an official ban on receiving and sending mail (mainly island countries).

 

We guarantee that you will receive your parcel with Xarelto without any problems at customs (we have our own delivery channels to countries with strict customs).

 

We guarantee a refund if your package has not been delivered to you for any reason, according to PayPal protection policy.

 

Due to Quarantine, delivery time may increase slightly, but still delivery remains within reasonable limits and does not exceed the delivery time during Christmas sales.

Full Description on English (PDF)